Navigation Links
Sinobiopharma Receives Trademark Approval and Authentication From Chinese Government For Its 'Tai' Drug Series

NANTONG CITY, China, June 18 /PRNewswire/ -- Sinobiopharma, Inc. ("Sinobiopharma" or, the "Company") (OTC Bulletin Board: SNBP) is pleased to announce today that it has received approval and authentication from the Trademark Bureau of China for its pre-surgical skeletal muscle relaxant Cisatracurium Besylate, marketed as Kutai, and its newly launched formulation of the anti-hypertension drug Perindopril, marketed as Yitai.

Kutai has gained rapid market acceptance and is building strong brand loyalty in China. Within 14 months of its launch there in late 2006, it has captured 80 percent of the Chinese market and is now in use in more than 700 hospitals across the country.

As the first Chinese produced Perindopril, Sinobiopharma's Yitai is a first-to-market (FTM) drug with significant competitive advantages. They include a higher price point that the Chinese government sets for FTM drugs and exclusivity for hospital contracts. Sinobiopharma's technology enables the production of a Perindopril formulation with lower cost active pharmaceutical ingredients (API), a high quality tablet and greater efficacy and reduced side effects compared to earlier versions of the drug. The technology also affords the potential for developing the world's first capsule formulation, which would make for easier swallowing.

The English name for the "Tai" trademark was taken from the Mandarin for "healthy". The name reflects Sinobiopharma's focus on health through the development of innovative, affordable therapies.

About Sinobiopharma

Sinobiopharma, Inc. is a fully integrated and highly innovative biotechnology company engaged in the research and development, manufacture and marketing of biopharmaceutical products in China, the world's fastest growing pharmaceutical market. Known as Dong Ying (Jiangsu) Pharmaceutical Co. Ltd. in China, the Company's current therapeutic focus is on anesthesia-assisted agents and cardiovascular drugs.

FORWARD LOOKING STATEMENTS This news release may include "forward-looking statements" regarding Sinobiopharma, Inc., and its subsidiaries, business and project plans. Such forward looking statements are within the meaning of Section 27A of the Securities Act of 1933, as amended, and section 21E of the United States Securities and Exchange Act of 1934, as amended, and are intended to be covered by the safe harbor created by such sections. Where Sinobiopharma, Inc. expresses or implies an expectation or belief as to future events or results, such expectation or belief is believed to have a reasonable basis. However, forward-looking statements are subject to risks, uncertainties and other factors, which could cause actual results to differ materially from future results expressed, projected or implied by such forward-looking statements. Sinobiopharma, Inc. does not undertake any obligation to update any forward-looking statement, except as required under applicable law.

SOURCE Sinobiopharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Sinobiopharma Reports Highlights of Third Quarter Results for Its Operating Subsidiary, Dong Ying China
2. Sinobiopharma, Inc. Signs Sales Contract for Flagship Project
3. Sinobiopharma Announces 350% Increase in Production of Its Flagship Drug in the First Quarter of 2009 Over the Same Period in 2008
4. Lake Elsinore Family Caregiver Receives Free Power Wheelchair From The SCOOTER Store
5. DaVita Receives Civil Complaint
6. Ranbaxy Receives Tentative Approval to Manufacture and Market Galantamine Tablets on an Exclusive Basis
7. Watson Receives First FDA Approval for Manufacturing Product at Its Goa, India Facility
8. Edwards Lifesciences Receives CE Mark for Edwards SAPIEN Transcatheter Heart Valve
9. PainCare Receives $14.4 Million in Cash From Completed Sale of South Florida Ambulatory Surgery Centers
10. UT Southwesterns obesity research receives $22 million NIH Roadmap grant
11. Temple Emergency Medicine receives $1.8M to find best MRSA treatment
Post Your Comments:
(Date:11/24/2015)... ... November 24, 2015 , ... ... been designated an Aetna Institute of Quality® Bariatric Surgery Facility for treating individuals ... and cost of health care services available to its members to help them ...
(Date:11/24/2015)... IL (PRWEB) , ... November 24, 2015 , ... Dr. Rodney E. Willey , ... His new venture, Koala Center for Sleep Disorders, provides treatment for snoring and sleep ... who have opened a Koala Center for Sleep Disorders in the US, one of four ...
(Date:11/24/2015)... Diego, CA (PRWEB) , ... November 24, 2015 ... ... the Silver&Fit® Exercise and Healthy Aging Program have announced their ... referral service. , “American Specialty Health Fitness is proud to have the MFN ...
(Date:11/24/2015)... N.Y. (PRWEB) , ... November 24, 2015 , ... Autism ... Tuesday, the global movement driven by social media and the generosity of people around ... then encourage their social media networks to give – and share the personal stories ...
(Date:11/24/2015)... Miami, FL (PRWEB) , ... November 24, 2015 ... ... manufacturer and engineer of patented products, announces Innovative Blending, a household invention that ... go. , "The Juice & Smoothie Bars market is worth $2 billion," says ...
Breaking Medicine News(10 mins):
(Date:11/24/2015)... NEWS, Va. , Nov. 24, 2015  DILON ... they have signed an agreement for DILON to distribute ... geographies across the globe. The signing of this distribution agreement ... Discovery NM750b Molecular Breast Imaging system and is considered ... to provide better healthcare solutions for clinicians and their ...
(Date:11/24/2015)... , Nov. 24, 2015 Avery Biomedical ... is pleased to announce the appointment of Anders ... Dr. Jonzon ... cardiology at Children,s Hospital, Uppsala University, Uppsala and Children,s ... 1984-1986, he was a fellow at the Cardiovascular Institute ...
(Date:11/24/2015)... LAUSANNE and BERN, Switzerland ... SA, the ARTORG Center for Biomedical Engineering Research of ... and the Division of Endocrinology, Diabetes and Clinical Nutrition ... announce the start of an exclusive collaboration to develop ... control algorithm for the personalised delivery of insulin for ...
Breaking Medicine Technology: